Public Employees Retirement System of Ohio Sells 3,275 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement System of Ohio trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,437 shares of the biopharmaceutical company's stock after selling 3,275 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Alnylam Pharmaceuticals were worth $13,322,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Los Angeles Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Breakwater Capital Group bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $249,000. Sanctuary Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $578,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Alnylam Pharmaceuticals by 22.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company's stock valued at $20,165,000 after buying an additional 13,422 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $7,009,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. TD Cowen upped their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a "sector outperform" rating in a research report on Friday, November 1st. Chardan Capital reiterated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $298.09.

Alnylam Pharmaceuticals Stock Down 3.5 %

Shares of ALNY stock traded down $8.89 during trading on Thursday, reaching $245.26. The company's stock had a trading volume of 751,052 shares, compared to its average volume of 862,094. The company has a market cap of $31.63 billion, a price-to-earnings ratio of -93.61 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business has a fifty day moving average price of $267.94 and a 200-day moving average price of $247.50. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. Alnylam Pharmaceuticals's quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 earnings per share. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,370 shares of company stock valued at $2,100,703. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.